The ADRB-2 antagonists propranolol and ICI-118,551 have shown therapeutic benefits on ccRCC in vitro and in vivo—triggering key processes like apoptosis, targeting and impairing the expression and signaling of key molecules such as HIF and NFĸB/p65, and showing anti-tumoral effects in vivo. The gene discussed is ADRB2; the disease is nonpapillary renal cell carcinoma.